Manufacturer switch of anti-seizure drugs may not increase the risk of seizure recurrence in Children: A nationwide study of prescription data in Germany

[1]  A. Ekici,et al.  Adherence to Antiepileptic Drugs and the Health Literacy of Caregivers in Childhood Epilepsy. , 2020, Puerto Rico health sciences journal.

[2]  H. Hamer,et al.  Switching the manufacturer of antiepileptic drugs is associated with higher risk of seizures: A nationwide study of prescription data in Germany , 2018, Annals of neurology.

[3]  W. Theodore,et al.  Generic antiepileptic drugs—Safe or harmful in patients with epilepsy? , 2018, Epilepsia.

[4]  H. Hamer,et al.  Adherence to antiepileptic drugs in children and adolescents: A retrospective study in primary care settings in Germany , 2017, Epilepsy & Behavior.

[5]  A. Kesselheim,et al.  Switching generic antiepileptic drug manufacturer not linked to seizures , 2016, Neurology.

[6]  H. Hamer,et al.  Nonadherence to antiepileptic drugs in Germany , 2016, Neurology.

[7]  R. Alfonso-Cristancho,et al.  Definition and Classification of Generic Drugs Across the World , 2015, Applied Health Economics and Health Policy.

[8]  H. Hamer,et al.  Sociodemographic Disparities in Administration of Antiepileptic Drugs to Adults with Epilepsy in Germany: A Retrospective, Database Study of Drug Prescriptions , 2014, CNS Drugs.

[9]  William H Shrank,et al.  Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. , 2013, JAMA internal medicine.

[10]  P. Kwan,et al.  Newer drugs for focal epilepsy in adults , 2012, BMJ : British Medical Journal.

[11]  B. Caffo,et al.  Assessing bioequivalence of generic antiepilepsy drugs , 2011, Annals of neurology.

[12]  J. Avorn,et al.  Refilling and Switching of Antiepileptic Drugs and Seizure‐Related Events , 2010, Clinical pharmacology and therapeutics.

[13]  Patrick Kwan,et al.  Definition of refractory epilepsy: defining the indefinable? , 2010, The Lancet Neurology.

[14]  Lawrence X. Yu,et al.  Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration , 2009, The Annals of pharmacotherapy.

[15]  K. Kostev,et al.  Validity and representativeness of the "Disease Analyzer" patient database for use in pharmacoepidemiological and pharmacoeconomic studies. , 2009, International journal of clinical pharmacology and therapeutics.

[16]  S. Candrilli,et al.  Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy , 2009, Epilepsy & Behavior.

[17]  E. Faught,et al.  Nonadherence to antiepileptic drugs and increased mortality , 2008, Neurology.

[18]  R. Gross,et al.  Generic substitution in the treatment of epilepsy , 2008, Neurology.

[19]  J. LeLorier,et al.  Clinical consequences of generic substitution of lamotrigine for patients with epilepsy , 2008, Neurology.

[20]  F. Andermann,et al.  Compulsory Generic Switching of Antiepileptic Drugs: High Switchback Rates to Branded Compounds Compared with Other Drug Classes , 2007, Epilepsia.

[21]  M. Prevett,et al.  Adherence to treatment in patients with epilepsy: Associations with seizure control and illness beliefs , 2006, Seizure.

[22]  Patrick Kwan,et al.  Drug development for refractory epilepsy: The past 25 years and beyond , 2017, Seizure.